Product Description
Rosuvastatin 20mg and olmesartan medoxomil 40mg
Mechanisms of Action: ARB,HMG-Coa Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Daewoong
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Hypertension|Dyslipidemia
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
DW_DWJ1276003 | P3 |
Completed |
Hypertension|Dyslipidemia |
2013-05-01 |
|
DW_DWJ1276002 | P1 |
Completed |
Healthy Volunteers |
2012-02-01 |